Polycystic Ovary Syndrome (PCOS) Market Size, Share & Industry Analysis, By Product Type (Oral Contraceptives, Insulin Sensitizing Agents, Anti-Androgens, Ovulation Inducing Agents, and Others), By Disease Type (Insulin-Resistant PCOS, Non-Insulin-Resistant PCOS, Post-Pill PCOS, Inflammatory PCOS, and Others), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global polycystic ovary syndrome (PCOS) market size was valued at USD 1.29 billion in 2024. The market is projected to grow from USD 1.38 billion in 2025 to USD 2.16 billion by 2032, exhibiting a CAGR of 6.67% during the forecast period.

Polycystic ovary syndrome is an endocrine and metabolic disorder that affects women of reproductive age. PCOS leads to hormonal imbalances, cysts in the ovaries, irregular periods, and excess androgen levels. Additionally, a lack of ovulation leads to an increase chance of infertility in females. The rising number of cases associated with PCOS in females, increasing the demand for active medication and lifestyle modification to decrease the symptoms. As it is a chronic condition cannot be cured. Thus, increasing demand for supportive medications is leading to the global market growth.

• For instance, February 2025 as to the data published by the WHO, polycystic ovarian syndrome (PCOS) affects around 6.0–13.0% of reproductive-aged women worldwide.

The market encompasses several major players, including Novo Nordisk A/S, Pfizer Inc., Bayer AG, and Sanofi, which have robust portfolios and strategic activities to support their dominance in the market.

MARKET DYNAMICS

MARKET DRIVERS

Increasing Prevalence of Infertility Associated with PCOS to Boost Market Growth

One of the most prominent driving factors of the market is the increasing number of cases of polycystic ovary syndrome in reproductive females and the rising prevalence of infertility among them. Infertility in young females hampers their mental well-being of females due to humiliation and severe physical suffering.

• For instance, in June 2025, as per the data published by NIH, around 124.7 million prevalent cases of PCOS related to infertility were reported globally in 2021, which is equivalent to an age-standardized point prevalence of 315.8 per 100,000 women.

Such high chances of increasing infertility among females propel the demand for adequate care and polycystic ovarian syndrome treatment, thus contributing to market grow.

MARKET RESTRAINTS

Limited Awareness and Increased Undiagnosed Population to Restrict Market Growth

PCOS majorly starts during adolescence, but due to a lack of awareness regarding the symptoms, many females remain undiagnosed. Such situations hamper the adoption of the products and market growth.

• For instance, in February 2025, as per the data published by the WHO, globally, polycystic ovary syndrome affects around 6.0–13.0% of reproductive-aged women, but around 70.0% of females remain undiagnosed.

MARKET OPPORTUNITIES

Development of Drugs Specifically for PCOS to Create Lucrative Growth Opportunities

Currently, there is no approved treatment for the cure of PCOS. The available treatment for PCOS is supportive and is used to reduce symptoms associated with PCOS, such as high blood sugar, irregular menstrual periods, excessive facial and body hair, and acne. Thus, this led to a shift in the focus of key pharmaceutical players to develop and launch approved drugs for the treatment of PCOS, offering a lucrative opportunity for growth in the market.

• For instance, in November 2021, Oxolife S.L. collaborated with the Reproductive Health research group at the University of Córdoba, Spain, and the Human Growth and Reproductive Development research group at Rutgers University in New Jersey to study the drug OXO-001. This was designed to enhance embryo implantation and address infertility issues related to polycystic ovary syndrome.

POLYCYSTIC OVARY SYNDROME (PCOS) MARKET TRENDS

Rapid Uptake of GLP-1 Agonists in PCOS Symptom Management to Support Market Growth

The rapid adoption of GLP-1 receptor agonists in the management of PCOS marks a significant shift in treatment strategies. Originally, these drugs were development for the treatment of diabetes. Still, there are benefits associated with weight loss, insulin sensitivity, and hormonal regulation, leading to an increase in the number of research for the adoption of these drugs in PCOS.

Additionally, the effective results of this drug in maintaining blood sugar levels and weight loss have fueled demand.

• For instance, in September 2023, a study in the Journal of Clinical Medicine examined 27 women with PCOS and obesity unresponsive to lifestyle changes, treated with weekly 0.5 mg subcutaneous semaglutide. After three months, participants experienced an average weight loss of 7.6 kg and a BMI reduction of 3.1; approximately 80% achieved at least a 5% weight loss.

Such clinical evidence increases the demand for GLP-1 agonists and thus acts as a global trend in the market.

MARKET CHALLENGES

Lack of Treatment Adherence to Challenge Market Growth

The longer duration of treatment, no relief of symptoms, side effects, and lack of knowledge regarding the disease and its management, are the common challenges faced by women’s lead to poor treatment adherence. Thus, these barriers are challenging the market growth.

• For instance, in 2022, a study published in the Journal of Family Medicine and Primary Care reported on a cross-sectional study among 224 women with PCOS, who were interviewed to analyze treatment adherence and barriers to PCOS treatment. It was found that 32.1% were fully adherent, 36.3% were partially adherent, and 31.6% were non-adherent.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type

Increasing Focus on Maintaining Menstrual Cycle Boosted Demand for Oral Contraceptives

On the basis of drug class, the market is classified into oral contraceptives, insulin-sensitizing agents, anti-androgens, ovulation-inducing agents, and others.

The oral contraceptives segment held the maximum global polycystic ovary syndrome (PCOS) market share in 2024. The dominant share of the segment is due to increasing demand for regulating the menstrual cycle, as it is the most common symptom of PCOS. Furthermore, increasing new product launches is expected to boost the segment’s growth.

• For instance, in August 2023, Xiromed LLC received approval from the U.S. Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for Joyeaux. It is a Levonorgestrel and Ethinyl Estradiol Tablet used as an oral contraceptive.

To know how our report can help streamline your business, Speak to Analyst

By Disease Type

Increased Prevalence of Insulin-Resistant PCOS Bolstered Segment Growth

In terms of disease type, the market is categorized into insulin-resistant PCOS, non-insulin-resistant PCOS, post-pill PCOS, inflammatory PCOS, and others.

The insulin-resistant PCOS segment accounted for the largest market share in 2024. In 2025, the segment is anticipated to dominate with a 64.4% share. The dominant share of the segment is due to insulin-resistant PCOS is a prominent type in all diagnosed patients globally.

• For instance, as per the March 2022 data published by NIH, insulin resistance (IR) is a prominent feature of PCOS with a prevalence of 35.0%-80.0%. 

The non-insulin-resistant PCOS segment is expected to grow at a CAGR of 7.86% over the forecast period.  

By Route of Administration

Wide Availability and Approvals for Oral Drugs Boosted Segment Growth

Based on route of administration, the market is segmented into oral, parenteral, and topical.

The oral segment held the dominating position, accounting for 79.7% share of the market in 2024. The dominant share of the segment is due to the presence of a wide range of drugs for managing the PCOS symptoms in oral dosage form. Additionally, better bioavailability and improved adherence to long-term treatment are also contributing to segment growth.

• For instance, in August 2023, Dr. Reddy’s Laboratories launched Saxagliptin and Metformin Hydrochloride extended-release tablets in the U.S. market. Metformin is prescribed for PCOS to improve insulin sensitivity.

The oral segment is set to flourish with a growth rate of 8.21% over the forecast period.

By Distribution Channel

Patient Preference and Ease of Availability Propelled Drug Stores and Retail Pharmacies Segment Growth

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

In 2024, the retail pharmacies & drug stores segment is expected to witness a leading growth trajectory. The segment is set to hold 62.9% share in 2025.  The recent launches of OTC-based drugs used to manage the symptoms of PCOS are contributing to the segment’s growth. Additionally, the ease of prescription filling for longer-term therapies is boosting the distribution of drugs through these channels.

• For instance, in July 2023, Perrigo Company plc announced that the U.S.FDA had approved the OTC sale of non-prescription Opill, an oral contraceptive.

The hospital pharmacies segment is projected to grow at a CAGR of 5.75% during the study period.

Polycystic Ovary Syndrome (PCOS) Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 0.42 billion, and also took the leading share in 2025 with USD 0.44 billion. North America’s dominance in the market is driven by factors such as increasing awareness and government initiatives regarding PCOS, as well as a focus on women's health in this region, which is expected to boost market growth. Additionally, the increased focus of pharmaceutical players on entering the region is expected to propel market growth.

• For instance, in September 2025, Renata entered the Canadian pharmaceutical market with the launch of a birth control pill.

In 2025, the U.S. market is estimated to reach USD 0.42 billion. The U.S. is expected to dominate the North America region's market, owing to the rising cases of polycystic ovary syndrome and the presence of adequate programs for better patient care. Additionally, the presence of key players in the market with strong research and development initiatives boosts the country’s growth in the market.

Europe

Europe is projected to record a growth rate of 6.90%, the second-highest among all regions, and reach a valuation of USD 0.40 billion by 2025. The increasing polycystic ovary syndrome and programs for adequate treatment primarily drive this. Backed by these factors, countries including the U.K. are expected to record the valuation of USD 0.08 billion, Germany to record USD 0.09 billion, and France to record USD 0.07 billion in 2025.

Asia Pacific

The Asia Pacific market is estimated to reach USD 0.38 billion by 2025 and secure the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 0.12 billion and USD 0.13 billion, respectively, in 2025.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions would witness a moderate growth in the coming years. The Latin America market is expected to reach a valuation of USD 0.09 billion in 2025. Lack of awareness and longer treatment duration contribute to a slower rate. In the Middle East & Africa, the GCC is set to reach a value of USD 0.03 billion in 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Leading Companies Emphasize Product Offerings and Strong Research and Development Activities to Maintain Their Positions

The global polycystic ovary syndrome (PCOS) market exhibits a fragmented structure, with large companies actively operating globally. These players have a robust product portfolio, backed by strong research and development capabilities. Sandoz, Pfizer Inc., Novo Nordisk A/S, and Ferring are some of the dominating players in the market. The company offers a comprehensive product range designed to improve insulin sensitivity.

Apart from this, other prominent players in the market include Bayer AG, Takeda Pharmaceutical, Merck Co. & Inc., among other major key players in the market. These key players are focusing on offering a range of products for the treatment of polycystic ovary syndrome to enhance their market presence.

LIST OF KEY POLYCYSTIC OVARY SYNDROME COMPANIES PROFILED

• Novo Nordisk A/S (Denmark)
• Pfizer Inc. (U.S.)
• Merck Co. & Inc. (Germany)
• Bayer AG (Germany)
• Sanofi (France)
• Ferring (Switzerland)
• Novartis AG (Switzerland)

KEY INDUSTRY DEVELOPMENTS

• August 2025 - Teva Pharmaceutical Industries Ltd. announced the U.S. FDA approval and launch of a generic version of Saxenda (liraglutide injection). This drug is indicated for weight loss.
• May 2025- ASKA Pharmaceutical Co., Ltd. received the manufacturing and marketing authorization for Slinda 28, a progestogen-only oral contraceptive, in Japan.
• January 2025- Mantra Pharma announced the launch of M-METFORMIN. This product is added to the company’s generic range and is used for maintaining blood sugar levels in PCOS patients.
• April 2023- Celix Pharma announced the launch of Sitagliptin and Metformin 50mg/1000mg film-coated tablets. Indicated for type 2 diabetes in adult patients, it can also be use for PCOS symptoms.
• April 2021- Mayne Pharma announced that the U.S. Food and Drug Administration (FDA) has approved NEXTSTELLIS contraceptive pill for the prevention of pregnancy.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation